Skip to content

To Evaluate the Efficacy and Safety of Aspherical Soft Contact Lens in Myopia Control

A Prospective Randomized Control Study to Evaluate the Effect of Ticon Aspherical Daily Disposable Soft Contact Lens on Myopia Control

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04238897
Enrollment
72
Registered
2020-01-23
Start date
2016-05-04
Completion date
2019-06-06
Last updated
2020-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

myopia control, soft contact lens, eye diseases

Brief summary

The objective of this study is to demonstrate that the Ticon Aspherical Daily Disposable Soft Contact Lens could retard myopia progress in youth

Detailed description

This study is designed as a prospective, multicenter, randomized, double blinded, controlled, paired-eye comparison study. At least 60 evaluable subjects with myopia progression ≧ 0.75 D in the past 12 months will be recruited from 2 study sites. The experimental soft contact lens with aspherical design (Ticon Aspherical) will be randomly assigned to either the right eye or the left eye of the subject , then the fellow eye will be assigned a control lens with a single vision distance (SVD) soft contact lens (Ticon). Both lenses will be worn at least 8 hours a day, 5 days a week for 1 year. All lenses will be replaced every day. Brief assessment of the clinical findings will be followed up for one year at 1 day, 1 week, 1, 3, 6, 9, 12 months upon allocation. The primary efficacy outcome is change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction over 12 months. The secondary outcome is change in axial eye length (AXL) measured over 12 months. The secondary outcome measure is used to corroborate any changes in SER

Interventions

Sponsors

National Taiwan University Hospital
CollaboratorOTHER
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
CollaboratorOTHER
APP Vision Care Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

paired-eye design

Eligibility

Sex/Gender
ALL
Age
9 Years to 15 Years
Healthy volunteers
No

Inclusion criteria

* Myopia (SE) between -1.00D to -8.00D * Astigmatism less than or equal to 1.75D * Myopia progression ≧0.75 D in the past 12 months * Best Corrected Visual Acuity (BCVA): 0.9 Snellen or better * Willingness to wear contact lens constantly * Availability for follow-up for at least 1 year * Parent's understanding and acceptance * have an acceptable surrogate capable of giving legally authorized consent on behalf of the subject

Exclusion criteria

* Anisometropia greater than 2.00D * Presence of ocular disease preventing wear of contact lens * Severe ocular or systemic allergies * Taking any medication that might have an impact on contact lens wear or that might influence the outcome of the clinical trial * Ocular or systemic condition that might affect refractive development * Atropine/Pirenzepine treatment for myopia control in the past 1 month * Prior use of Ortho-K lenses * Dry eye with Schimer Test (basal secretion test) \< 5mm/5min or other physical condition that would contraindicate contact lens wear

Design outcomes

Primary

MeasureTime frameDescription
Spherical Equivalent Refraction (SER)12 monthsThe change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction over 12 months.

Secondary

MeasureTime frameDescription
Axial Eye Length (AXL)12 monthsThe change in axial eye length (AXL) measured over 12 months. Axial length is measured after cycloplegia using optical biometry.

Other

MeasureTime frameDescription
Primary safety Endpoints12 monthsAll dispensed eyes over all follow-up visits. Measured on a scale of 0-4 with 0=no findings and 4=severe findings. Epithelial edema, epithelial microcysts, corneal staining, limbal & bulbar injection, conjunctival abnormalities, corneal neovascularization and infiltrates will be measured.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026